在肝细胞癌中对m6A阅读器YTHDF2预后,免疫透和相关调节网络的全面分析

Hang Wang1,2, Hui Cai1, Li Li1,2

  • 1Shengli Clinical Medical College of Fujian Medical University, Department of Health Management, Fujian Provincial Hospital, Fuzhou, Fujian, China.

Heliyon
|January 1, 2024
PubMed
概括

N6-甲基氨酸 (m6A) 调节剂YTHDF2在肝细胞癌 (HCC) 中被上调,与预后不佳相关,并影响瘤微环境. 这项研究确定了YTHDF2作为HCC的潜在预后生物标志物,为治疗策略提供了洞察力.

相关概念视频